Related coverage linked through entity extraction aliases.
Jul 15, 2026
Prime Medicine receives a Buy upgrade from H.C. Wainwright after New Zealand clears its first in vivo prime editing trial for Wilson's disease. The FDA also granted RMAT designation to its CGD therapy PM359. Jacob Funds and ARK Investment have recently added to their positions in the gene-editing company.
May 12, 2026
A review in Genes & Diseases says robust non-clinical safety assessment is critical for CRISPR-based gene therapies. It highlights genotoxic, delivery, and immunological risks and recommends risk-based development programs.
Mar 21, 2026
The FDA has issued draft guidance creating a "Plausible Mechanism Framework" to accelerate approval of individualized therapies for ultra-rare diseases where traditional clinical trials are not feasible. The guidance focuses on gene editing and RNA-based treatments targeting specific genetic abnormalities.
Mar 14, 2026
Scientists have developed multiple breakthrough delivery systems for gene editing and mRNA therapies, including a simple amino acid supplement that increases delivery 20-fold and a CRISPR gene drive that reverses antibiotic resistance in bacterial populations.
Feb 26, 2026
The global biotechnology market is undergoing a transformation from discovery-based science to precision engineering, driven by AI, synthetic biology, and gene editing technologies, with projected growth of 13-15% over the next five years.
Feb 24, 2026
The global CRISPR and prime editing market is forecast to grow at 24.1% CAGR through 2031, driven by therapeutic advances and regulatory progress. Scribe Therapeutics achieved a second milestone with Eli Lilly, while new RNA production and gene editing technologies accelerate research.
